Basel, 4 November 2013 – Roche licenses investigational antibiotic POL7080 from Polyphor. POL7080 targets Pseudomonas species with a novel mode of action. This “superbug” bacterium is commonly found in hospitals and has evolved to become resistant to many antibiotic treatments. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Polyphor Ltd., a privately held pharmaceutical company, announced today […]
Gazyva demonstrated an 84 percent reduction in the risk of disease worsening or death when combined with chemotherapy compared to chemotherapy alone Gazyva is the first medicine approved with the FDA’s Breakthrough Therapy Designation Basel, 1 November 2013 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved […]
TUCSON, Arizona and INGELHEIM, Germany, 19 September 2013 – Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, and Boehringer Ingelheim (BI) announced today that they have entered into an agreement to collaborate on the development of companion diagnostic tests for Boehringer Ingelheim Oncology programmes. As part of the agreement, Ventana will utilize its […]